Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACERNYSE:ANRONASDAQ:BYSINASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACERAcer Therapeutics$0.66$0.74$0.55▼$4.56$16.15MN/AN/A574,675 shsANROAlto Neuroscience$2.26+1.3%$2.45$1.60▼$17.55$61.45M1.93396,198 shs149,415 shsBYSIBeyondSpring$3.11-8.5%$1.84$0.98▼$3.44$125.38M0.0729,274 shs213,609 shsSKYESkye Bioscience$2.14+3.4%$2.13$1.14▼$9.73$66.30M1.69365,298 shs99,900 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACERAcer Therapeutics0.00%0.00%0.00%0.00%0.00%ANROAlto Neuroscience+0.89%-9.42%-11.72%-15.95%-79.71%BYSIBeyondSpring-8.53%+6.87%+86.23%+86.23%+9.51%SKYESkye Bioscience+3.13%-1.38%-0.47%+13.23%-77.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACERAcer TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AANROAlto Neuroscience1.4959 of 5 stars3.31.00.00.00.60.81.3BYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/ASKYESkye Bioscience1.9496 of 5 stars3.52.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACERAcer Therapeutics 0.00N/AN/AN/AANROAlto Neuroscience 2.57Moderate Buy$15.40581.42% UpsideBYSIBeyondSpring 0.00N/AN/AN/ASKYESkye Bioscience 3.00Buy$16.60675.70% UpsideCurrent Analyst Ratings BreakdownLatest ACER, BYSI, ANRO, and SKYE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/15/2025ANROAlto NeuroscienceWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.004/7/2025ANROAlto NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.003/21/2025ANROAlto NeuroscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/21/2025SKYESkye BioscienceCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.003/21/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACERAcer TherapeuticsN/AN/AN/AN/AN/AN/AANROAlto NeuroscienceN/AN/AN/AN/A$5.62 per shareN/ABYSIBeyondSpring$1.75M71.65N/AN/A($0.37) per share-8.41SKYESkye BioscienceN/AN/AN/AN/A$2.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACERAcer Therapeutics-$26.24MN/A0.00∞N/AN/AN/AN/AN/AANROAlto Neuroscience-$61.43M-$2.34N/AN/AN/AN/A-39.35%-33.86%8/12/2025 (Estimated)BYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/ASKYESkye Bioscience-$26.57M-$0.82N/AN/AN/AN/A-53.92%-48.58%N/ALatest ACER, BYSI, ANRO, and SKYE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ANROAlto Neuroscience-$0.59-$0.53+$0.06-$0.56N/AN/A5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/A3/20/2025Q4 2024ANROAlto Neuroscience-$0.65-$0.56+$0.09-$0.56N/AN/A3/20/2025Q4 2024SKYESkye Bioscience-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACERAcer TherapeuticsN/AN/AN/AN/AN/AANROAlto NeuroscienceN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACERAcer TherapeuticsN/AN/AN/AANROAlto Neuroscience0.1522.5322.53BYSIBeyondSpringN/A2.492.49SKYESkye BioscienceN/A11.8511.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACERAcer TherapeuticsN/AANROAlto NeuroscienceN/ABYSIBeyondSpring40.29%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipACERAcer Therapeutics20.20%ANROAlto Neuroscience11.13%BYSIBeyondSpring29.31%SKYESkye Bioscience4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACERAcer Therapeutics3024.46 million19.52 millionNot OptionableANROAlto NeuroscienceN/A27.07 million24.06 millionN/ABYSIBeyondSpring8040.32 million28.50 millionOptionableSKYESkye Bioscience1130.98 million29.58 millionOptionableACER, BYSI, ANRO, and SKYE HeadlinesRecent News About These CompaniesSkye confirms phase 2 data on nimacimab for obesity expected later this yearJune 19 at 10:46 AM | msn.comSkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific SessionsJune 17 at 8:23 AM | finance.yahoo.comSkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific SessionsJune 17 at 7:00 AM | globenewswire.comCantor Fitzgerald Weighs in on Skye Bioscience FY2026 EarningsJune 12, 2025 | marketbeat.comCantor Fitzgerald Predicts Skye Bioscience FY2026 EarningsJune 10, 2025 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Buy" from AnalystsJune 8, 2025 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by BrokeragesJune 8, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Trading Up 24% - Here's What HappenedMay 31, 2025 | marketbeat.com3 Stocks Targeting Weight Loss Market With Cannabinoid-Based TherapiesMay 23, 2025 | zacks.comSkye Bioscience to Participate in Upcoming Investment ConferencesMay 22, 2025 | globenewswire.comSkye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity TreatmentMay 21, 2025 | nasdaq.comQ&A: Next wave of obesity drugs may ‘afford a lot of advantages’May 20, 2025 | healio.comArecor shares climb 18% on collaboration with Skye BioscienceMay 19, 2025 | lse.co.ukArecor establishes partnership with Skye Bioscience to develop enhanced formulation of obesity candidate NimacimabMay 19, 2025 | cambridgenetwork.co.ukSkye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate NimacimabMay 19, 2025 | finanznachrichten.deArecor enters formulation partnership with Skye BioscienceMay 19, 2025 | sharecast.comArecor shares jump 10% on obesity drug partnership with Skye BioscienceMay 19, 2025 | proactiveinvestors.co.ukArecor partners with Skye Bioscience to improve formulation of obesity drugMay 19, 2025 | proactiveinvestors.co.ukSkye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate NimacimabMay 19, 2025 | globenewswire.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 13, 2025 | globenewswire.comSkye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on ObesityMay 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACER, BYSI, ANRO, and SKYE Company DescriptionsAcer Therapeutics NASDAQ:ACERAcer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.Alto Neuroscience NYSE:ANRO$2.26 +0.03 (+1.35%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$2.25 -0.01 (-0.44%) As of 06/18/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.BeyondSpring NASDAQ:BYSI$3.11 -0.29 (-8.53%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$3.07 -0.04 (-1.29%) As of 06/18/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Skye Bioscience NASDAQ:SKYE$2.14 +0.07 (+3.38%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.08 -0.06 (-3.04%) As of 06/18/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
